

Fosun Newsletter

Fosun International Limited (00656.HK)
www.fosun-international.com

June 2010



Stock information

Stock (30/06/2010).....HKD 5.50
52-week range.....HKD 2.78-6.70
Shares (mn shares).....6,422
Market value (HKD \$bn)..... 35.32

Core businesses ⁽¹⁾

Pharmaceuticals

... Fosun Pharma (600196.SH)48.05%
..... Sinopharma (01099.HK)16.34%

Property Development

..... Forte (02337.HK)70.6%
.....Shanghai Zendai (0755.HK)12.9%

Steel

..... NSU 60.0%
..... Jianlong Group 26.7%

Mining

..... Hainan Mining 60.0%
..... Huaxia Mining 18.4%
..... Shanjiao Wulin 20.0%
..... Zhaojin Mining (01818.HK)8.2%

Retail, Services & Strategic Investments

... Yuyuan (600655.SH)17.3%
..... Focus Media (NASDAQ:FMCN):25.8%
..... Yong'an Insurance 14.6%
..... Club Med (EPA:CU) 7.1%⁽²⁾
.....PE Platform⁽³⁾


Notes:

(1) Effective Shareholding.

(2) Assuming a 100% redemption in shares of all the ORANEs mandatorily convertible bonds issued by Club Med.

(3) Fosun's PE investment platforms include Fosun Capital, Fosun Venture Capital, Fosun Principal Capital and Fosun-Carlyle. Fosun Group's effective stakes in the four are 100%,100%,99% and 50%, respectively.

Strategic partnership between Fosun International and Club Med



Links to Relevant Information

Fosun International

www.fosun-international.com

Pharmaceuticals

www.fosunpharma.com

Property Development

www.forte.com.cn

Steel

www.njsteel.com.cn

www.ejianlong.com

Mining

www.hnmining.com

www.zhaojin.com.cn

Retail, Services & Strategic

Investments

www.yuyuantm.com.cn

www.focusmedia.cn

www.yaic.com.cn

Contact us

Email: IR@fosun.com

Direct Line: (8621) 6332 5162

Address: No.2 East Fuxing Road

Stephanie, Shi Qifang

Helena, Huang Hui

"The strategic partnership between Fosun and Club Med well demonstrates Fosun's consisting strategy of being rooted in China and investing in the drivers of China's economic development . It also marks another important step on Fosun's road to globalization. Fosun has a diversified industrial base and resources, and is able to lend full support to Club Med's expansion in China. Fosun will not only support Club Med's global strategy of upscale positioning and sharing of China's growth opportunities, but will also use this opportunity to benchmark itself with international brands and standards in order to improve its ability to consolidate resources and manage its investment."



—Mr. Guo Guangchang, Chairman of Fosun International

Investment

Execution of value investment principles in combine of domestic demand investment theme

Subscribe for Forte's Newly Issued Domestic Shares

- Subscriber: Fosun Group
- Subscription price: RMB 1.85 per share (equal to approximately 0.8*09PB)
- Number of domestic shares: Fosun Group has agreed to subscribe for 389,950,000 new domestic shares, representing approximately 13.36% of the enlarged issued share capital of Forte
- Shareholding: after the completion of the issuance, the attributable shareholding by Fosun International in Forte will increase from 70.56% to 74.49%
- Significance:
 - (1) It is in line with Fosun's investment theme of domestic demand as well as its optimistic view of the mid-to-long term prospect of China's property market;
 - (2) It will help to improve Forte's capital structure and cash flow condition, and upgrade its overall profitability.

Acquire 30% transferred shares of Haizhimen

- Acquirer: Fosun Group
- Transaction Amount: RMB 1.6 bn
- Significance:
 - (1) This transfer allows Forte to realize its 30% equity interest in Haizhimen project company which can be used to restructure its capital portfolio and improve cash flow condition;
 - (2) Haizhimen project company intends to focus its future investments in property market, which is also in line with Fosun's optimistic view of the mid-to-long term prospect of China's property market.

Fosun Pharma's Collaboration with Chindex resources, and complementary strengths

An integration and unification of concepts, matching

➤ Equity investment through secondary market

- Investor: Fosun Pharma
- Investment : US\$ 22.73 million ⁽¹⁾
- Stake: 10.58% of Chindex's common shares outstanding and 11.48% of its ordinary A shares, as of the close of NASDAQ on June 10, 2010

Note: (1) accumulated number, as of the close of NASDAQ on June 29, 2010

➤ Full collaboration

- Placement:
 - (1) Chindex will conditionally issue about 1.99 million shares in total in two batches at the price of US\$ 15 per share to Fosun Pharma, with a total value of US\$ 29.86 million;
 - (2) Upon the completion of the two placements, Fosun Pharma could appoint two representatives as the board of director of Chindex;
 - (3) Fosun Pharma could hold no more than 25% of Chindex's common shares outstanding through purchase or other transactions.
- Business cooperation: A joint venture will be established and the medical apparatus and instrument businesses of the two parties will be merged. Fosun Pharma will hold 51% of the joint venture's equity.
- Significance:
 - (1) By integrating medical apparatus and instrument businesses, Fosun Pharma will form a complete industry chain system covering R&D, manufacturing, domestic and overseas distribution of medical apparatus and instruments, and will further speed up the development of medical apparatus and instrument business;
 - (2) Chindex will continue to focus on the building and expanding of "United Family Hospital and Clinics" which is a premium brand in healthcare services. Fosun Pharma will also continue to support and accelerate its development of a multilevel, diversified, and extensive high-end healthcare service, and to share the rapid development of premium medical service industry in the country.

Honors Development propelled by brand and culture

- Mr. Guo Guangchang, Chairman of Fosun Group, won the award of "BUSINESS LEADERS THAT CHANGE CHINA'S COMMERCE " hosted by "Global Entrepreneurs";
- Mr. Liang Xinjun, Vice Chairman and CEO of Fosun Group, won the honor of the sixth "Chinese Successful Youth Leader";
- Fosun Pharma ranked the third on "Top 100 for Market Value Management of Listed Companies in China 2010 ";
- The microorganism detection project by Fosun Pharma was named "Demonstrative Project for National High-tech Industrialization" by National Development and Reform Commission;
- NSU won the award of "2009 Nanjing Mayor Quality Award". At the same time, it won a medal for "Demonstrative Base for Excellent Performance Management in Nanjing";
- On the award ceremony of the fifth Chinese Security Journal Cup on Survey of Competitiveness and Creditability of listed companies, Yuyuan won the title of "Highest Attention to Shareholders' Interest".

Disclaimer

This document herewith includes forward-looking statements. All statements, other than statements of historical facts, that address activities, events or developments that Fosun International Limited and its portfolio companies expects or anticipates will or may occur in the future (including but not limited to projections, targets, estimates and business plans) are forward-looking statements. The Company's actual results or developments may differ materially from those indicated by these forward-looking statements as a result of various factors and uncertainties, and other risks and factors beyond our control. In addition, the Company makes the forward-looking statements referred to herein as of today and undertakes no obligation to update these statements.